Table 1: Patient Demographics

|  | **Whole Cohort** | | **Survival 6 months post CC** | | | **Return to ACT** | | | **ECOG PS >2 (N=221)** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **N** | **N = 373**1 | **Yes**,  N = 1361 | **No**,  N =  2371 | **p-value**2 | **No**,  N = 2371 | **Yes**, N = 1361 | **p-value**2 | **N** | **No**,  N = 1521 | **Yes**, N = 691 | **p-value**2 |
| **Age on admission** | 373 | 64 (55 – 72) | 65 (58 – 73) | 64 (55 – 72) | 0.43 | 65 (55 – 73) | 64 (55 – 71) | 0.44 | 221 | 64 (55 – 74) | 67 (59 – 73) | 0.18 |
| **Sex** | 373 |  |  |  | 0.98 |  |  | 0.65 | 221 |  |  | **0.043** |
| Female |  | 178 (48) | 65 (48) | 113 (48) |  | 111 (47) | 67 (49) |  |  | 68 (45) | 41 (59) |  |
| Male |  | 195 (52) | 71 (52) | 124 (52) |  | 126 (53) | 69 (51) |  |  | 84 (55) | 28 (41) |  |
| **BMI** | 342 | 26.0 (22.2 – 29.4) | 25.8 (22.2 – 29.7) | 26.1 (22.2 – 28.9) | 0.80 | 26.0 (22.1 – 28.9) | 25.9 (22.3 – 29.9) | 0.72 | 198 | 25.1 (21.8 – 28.8) | 26.4 (22.4 – 29.7) | 0.25 |
| **ECOG PS at referral to Oncology** | 358 |  |  |  | 0.062 |  |  | 0.80 | 212 |  |  | **0.005** |
| 0 |  | 131 (37) | 51 (38) | 80 (36) |  | 83 (37) | 48 (36) |  |  | 54 (37) | 23 (35) |  |
| 1 |  | 162 (45) | 65 (49) | 97 (43) |  | 98 (44) | 64 (48) |  |  | 76 (52) | 25 (38) |  |
| 2 |  | 42 (12) | 10 (7.5) | 32 (14) |  | 26 (12) | 16 (12) |  |  | 14 (9.6) | 10 (15) |  |
| 3 |  | 21 (5.9) | 5 (3.8) | 16 (7.1) |  | 15 (6.7) | 6 (4.5) |  |  | 2 (1.4) | 6 (9.1) |  |
| 4 |  | 2 (0.6) | 2 (1.5) | 0 (0) |  | 2 (0.9) | 0 (0) |  |  | 0 (0) | 2 (3.0) |  |
| **ECOG PS on admission** | 370 |  |  |  | **0.014** |  |  | **0.032** | 220 |  |  | **<0.001** |
| 0 |  | 45 (12) | 24 (18) | 21 (9.0) |  | 25 (11) | 20 (15) |  |  | 24 (16) | 8 (12) |  |
| 1 |  | 138 (37) | 51 (38) | 87 (37) |  | 81 (34) | 57 (42) |  |  | 66 (43) | 14 (21) |  |
| 2 |  | 121 (33) | 46 (34) | 75 (32) |  | 76 (32) | 45 (33) |  |  | 49 (32) | 28 (41) |  |
| 3 |  | 49 (13) | 11 (8.1) | 38 (16) |  | 38 (16) | 11 (8.1) |  |  | 7 (4.6) | 14 (21) |  |
| 4 |  | 16 (4.3) | 3 (2.2) | 13 (5.6) |  | 14 (6.0) | 2 (1.5) |  |  | 5 (3.3) | 4 (5.9) |  |
| 5 (Cardiac Arrest) |  | 1 (0.7) | 1 (0.7) | 0 (0) |  | 1 (0.4) | 0 (0) |  |  | 1 (0.7) | 0 (0) |  |
| **Charlson Comorbidity Index (CCI)** | 373 | 8.00 (7.00 – 9.00) | 8.00 (7.00 – 9.00) | 8.00 (7.00 – 9.00) | 0.78 | 8.00 (7.00 – 9.00) | 8.00 (7.00 – 9.00) | 0.31 | 221 | 8.00 (6.75 – 9.00) | 9.00 (7.00 – 11.00) | **<0.001** |
| **Diagnosis categories** | 372 |  |  |  |  |  |  |  | 220 |  |  |  |
| Brain |  | 22 (5.9) | 7 (5.2) | 15 (6.3) |  | 15 (6.4) | 7 (5.1) |  |  | 12 (7.9) | 3 (4.3) |  |
| Breast |  | 58 (16) | 24 (18) | 34 (14) |  | 30 (13) | 28 (21) |  |  | 23 (15) | 13 (19) |  |
| Breast and Lower GI |  | 1 (0.3) | 1 (0.7) | 0 (0) |  | 1 (0.4) | 0 (0) |  |  | 0 (0) | 1 (1.4) |  |
| CUP |  | 4 (1.1) | 0 (0) | 4 (1.7) |  | 4 (1.7) | 0 (0) |  |  | 0 (0) | 1 (1.4) |  |
| Endocrine |  | 14 (3.8) | 3 (2.2) | 11 (4.6) |  | 12 (5.1) | 2 (1.5) |  |  | 6 (4.0) | 3 (4.3) |  |
| Germ Cell |  | 2 (0.5) | 0 (0) | 2 (0.8) |  | 1 (0.4) | 1 (0.7) |  |  |  |  |  |
| Gynae |  | 36 (9.7) | 10 (7.4) | 26 (11) |  | 22 (9.3) | 14 (10) |  |  | 12 (7.9) | 9 (13) |  |
| H&N |  | 12 (3.2) | 3 (2.2) | 9 (3.8) |  | 7 (3.0) | 5 (3.7) |  |  | 3 (2.0) | 3 (4.3) |  |
| Lower GI |  | 44 (12) | 18 (13) | 26 (11) |  | 32 (14) | 12 (8.8) |  |  | 22 (15) | 4 (5.8) |  |
| Lung |  | 46 (12) | 14 (10) | 32 (14) |  | 26 (11) | 20 (15) |  |  | 16 (11) | 8 (12) |  |
| Lung and breast |  | 1 (0.3) | 0 (0) | 1 (0.4) |  | 1 (0.4) | 0 (0) |  |  | 1 (0.7) | 0 (0) |  |
| Melanoma |  | 20 (5.4) | 7 (5.2) | 13 (5.5) |  | 13 (5.5) | 7 (5.1) |  |  | 10 (6.6) | 1 (1.4) |  |
| Melanoma and Urology |  | 2 (0.5) | 2 (1.5) | 0 (0) |  | 0 (0) | 2 (1.5) |  |  | 1 (0.7) | 0 (0) |  |
| Sarcoma |  | 12 (3.2) | 6 (4.4) | 6 (2.5) |  | 7 (3.0) | 5 (3.7) |  |  | 6 (4.0) | 2 (2.9) |  |
| Squamous cell carcinoma |  | 1 (0.3) | 1 (0.7) | 0 (0) |  | 0 (0) | 1 (0.7) |  |  | 1 (0.7) | 0 (0) |  |
| Upper GI |  | 30 (8.1) | 8 (5.9) | 22 (9.3) |  | 26 (11) | 4 (2.9) |  |  | 6 (4.0) | 10 (14) |  |
| Urology |  | 67 (18) | 31 (23) | 36 (15) |  | 39 (17) | 28 (21) |  |  | 32 (21) | 11 (16) |  |
| **GCS prior to CC admission** | 363 | 15.0 (14.0 – 15.0) | 15.0 (14.3 – 15.0) | 15.0 (13.0 – 15.0) | **0.013** | 15.0 (11.0 – 15.0) | 15.0 (15.0 – 15.0) | **<0.001** | 216 | 15.0 (14.3 – 15.0) | 15.0 (14.0 – 15.0) | 0.38 |
| **Rockwood Clinical Frailty Score on admission to CC** | 188 | 4 (3 - 6) | 4 (3 - 6) | 4 (3 - 6) | 0.99 | 4 (3 - 6) | 4 (3 - 6) | 0.99 | 108 | 4 (3 - 6) | 4 (3 - 6) | 0.91 |
| **APACHE2 score** | 201 | 20 (15 – 26) | 18 (14 – 25) | 21 (16 – 26) | 0.075 | 22 (17 – 27) | 18 (14 – 24) | **0.011** | 115 | 17 (14 – 24) | 21 (18 – 25) | 0.085 |
| **Modified**  **Apache score** | 236 | 17 (11 – 22) | 15 (10 – 20) | 17 (12 – 22) | **0.046** | 17 (12 – 22) | 15 (10 – 19) | **0.003** | 128 | 14 (10 – 19) | 17 (15 – 22) | **0.013** |
| **SOFA score** | 242 | 7.0 (4.0 – 11.0) | 6.0 (4.0 – 10.0) | 8.0 (4.0 – 11.0) | 0.10 | 8.0 (5.0 – 11.0) | 6.0 (3.0 – 9.0) | **0.003** | 128 | 6.0 (4.0 – 9.0) | 6.0 (4.0 – 9.0) | 0.92 |
| **Modified SOFA Score** | 211 | 5.00 (3.00 – 7.00) | 4.00 (2.00 – 6.00) | 6.00 (3.75 – 7.00) | **0.019** | 6.00 (4.00 – 7.00) | 5.00 (3.00 – 6.00) | **0.016** | 117 | 4.00 (2.00 – 6.00) | 5.00 (3.00 – 6.00) | 0.81 |
| **SAPS 2 score** | 212 | 48 (40 – 62) | 44 (37 – 56) | 50 (41 – 65) | **0.031** | 52 (42 – 67) | 43 (37 – 52) | **<0.001** | 117 | 42 (37 – 52) | 48 (41 – 56) | 0.17 |
| **Modified SAPS 2 score** | 187 | 45 (37 – 56) | 42 (35 – 52) | 46 (39 – 57) | **0.038** | 47 (39 – 60) | 41 (36 – 49) | **0.003** | 104 | 40 (35 – 47) | 44 (39 – 51) | **0.048** |
| **Died on critical care** | 320 | 34 (11) | 0 (0) | 34 (17) | **<0.001** | 34 (17) | 0 (0) | **<0.001** | 202 | 0 (0) | 0 (0) |  |
| **Number of Days in Critical Care** | 326 | 2.5 (1.0 – 5.0) | 2.0 (1.0 – 5.0) | 3.0 (1.0 – 6.0) | 0.21 | 3.0 (1.0 – 6.0) | 2.0 (1.0 – 4.0) | 0.25 | 197 | 2.0 (1.0 – 4.0) | 3.0 (2.0 – 6.0) | **0.048** |
| **Survived to discharge** | 371 | 371 (100) | 136 (100) | 235 (100) |  | 235 (100) | 136 (100) |  | 221 | 152 (100) | 69 (100) |  |
| **Survival from critical care (days)** | 301 | 112 (17 – 570) | 686 (359 – 1,052) | 28 (3 – 81) | **<0.001** | 44 (5 – 161) | 378 (118 – 949) | **<0.001** | 198 | 426 (141 – 957) | 95 (50 – 278) | **<0.001** |
| **ECOG PS on discharge from hospital** | 221 |  |  |  | **<0.001** |  |  | **<0.001** | 221 |  |  | **<0.001** |
| 0 |  | 6 (2.7) | 6 (4.7) | 0 (0) |  | 1 (1.0) | 5 (4.3) |  |  | 6 (3.9) | 0 (0) |  |
| 1 |  | 69 (31) | 52 (40) | 17 (18) |  | 20 (19) | 49 (42) |  |  | 69 (45) | 0 (0) |  |
| 2 |  | 77 (35) | 48 (37) | 29 (32) |  | 36 (35) | 41 (35) |  |  | 77 (51) | 0 (0) |  |
| 3 |  | 46 (21) | 18 (14) | 28 (30) |  | 31 (30) | 15 (13) |  |  | 0 (0) | 46 (67) |  |
| 4 |  | 23 (10) | 5 (3.9) | 18 (20) |  | 16 (15) | 7 (6.0) |  |  | 0 (0) | 23 (33) |  |
| **Survival at home (days)** | 126 | 136 (18 – 899) | 839 (365 – 1,078) | 32 (0 – 95) | **<0.001** | 68 (0 – 449) | 271 (76 – 951) | **0.002** | 81 | 314 (108 – 947) | 71 (20 – 355) | **0.005** |
| **ECOG PS >2** | 221 | 69 (31%) |  |  |  |  |  |  |  |  |  |  |
| **Further Oncology treatment** | 373 | 136 (36%) |  |  |  |  |  |  |  |  |  |  |
| **Survival 6 months post CC** | 373 | 237 (64%) |  |  |  |  |  |  |  |  |  |  |
| 1Median (IQR); n (%) | | | | | | | | | | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | | | | | | | | | | |